Financing ·
AIM ImmunoTech Inc. mutually terminated its Equity Distribution Agreement with Maxim Group LLC, effective August 15…
AIMIAIM ImmunoTech Inc.
AIM ImmunoTech Inc. mutually terminated its Equity Distribution Agreement with Maxim Group LLC, effective August 15, 2026, without incurring termination penalties. The agreement allowed the company to sell shares via at-the-market offerings from April 1, 2025, through July 31, 2026. During this period, the company sold 3,200,736 shares for aggregate gross proceeds of approximately $2.8 million. The termination prevents further share issuances under the existing agreement or related prospectus supplements. AIM ImmunoTech Inc. operates in the biotechnology industry, focusing on developing immunotherapies.